Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01894243 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 5 | Sep 13, 2019 | clinicaltrials |
| NCT03182257 | Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors(ONTRK) | terminated | Phase 1 | 1 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 2 | Sep 13, 2019 |
| clinicaltrials |
| NCT03081819 | A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer | completed | Phase 1 | 11 | Kyunghee University Medical CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT03583125 | Study of EOC317 in Chinese Patients With Advanced Solid Tumors | unknown | Phase 1 | 140 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02250170 | Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor | completed | Phase 1 | 47 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT02644278 | First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy | completed | Phase 1 | 15 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01061788 | A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007(RAP) | completed | Phase 1 | 43 | Jeffrey ClarkeOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03991559 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02748837 | A Study of ERY974 in Patient With Advanced Solid Tumors | completed | Phase 1 | 29 | Chugai PharmaceuticalINDUSTRY | 3 | Aug 22, 2019 | clinicaltrials |
| NCT02737072 | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | terminated | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT04049929 | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT03286296 | LZM009 to Treat Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Livzon Pharmaceutical Group Inc.INDUSTRY | 1 | Aug 2, 2019 | clinicaltrials |
| NCT03641794 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers | unknown | Phase 1 | 56 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02430311 | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | completed | Phase 1 | 36 | AstraZenecaINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT02648490 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | completed | Phase 1 | 19 | Henlix, IncINDUSTRY | 2 | Jul 30, 2019 | clinicaltrials |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT03494231 | A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 5 | Henlix, IncINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01945710 | An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors | completed | Phase 1 | 62 | Eisai LimitedINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02575638 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | unknown | Phase 1 | 65 | Cao Pharmaceuticals Inc.INDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02004717 | Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02058901 | Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors. | completed | Phase 1 | 101 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT03313557 | AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 4 | Jun 24, 2019 | clinicaltrials |
| NCT01898078 | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 26 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 21, 2019 | clinicaltrials |
| NCT02289196 | Safety Study of Vx006 Vaccine in Solid Tumor Patients | completed | Phase 1 | 23 | Vaxon BiotechINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03362723 | A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors | completed | Phase 1 | 48 | Hoffmann-La RocheINDUSTRY | 2 | Jun 19, 2019 | clinicaltrials |
| NCT01648764 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | completed | Phase 1 | 73 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT02476123 | Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 118 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 10, 2019 | clinicaltrials |
| NCT03757936 | A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT02250781 | Oral ONC201 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Rutgers, The State University of New JerseyOTHER | 1 | May 22, 2019 | clinicaltrials |
| NCT02324621 | Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Rutgers, The State University of New JerseyOTHER | 1 | May 22, 2019 | clinicaltrials |
| NCT03175497 | Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors | completed | Phase 1 | 15 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | May 13, 2019 | clinicaltrials |
| NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT00858377 | A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | completed | Phase 1 | 95 | AmgenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT02622932 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients | completed | Phase 1 | 6 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01877811 | Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors | completed | Phase 1 | 143 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT02548390 | Study of Intravenous RXDX-107 in Patients With Solid Tumors | terminated | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT01791088 | Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 56 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02540876 | Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery | completed | Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT00909831 | Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment | completed | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00390000 | Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 29 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01537107 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 31 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00003194 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | terminated | Phase 1 | 24 | Seattle Children's HospitalOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Sep 13, 2019source: clinicaltrials